Pyk2 promotes tumor progression in renal cell carcinoma

Zhao,Tangliang; Bao,Yi; Lu,Xin; He,Yi; Gan,Xinxin; Wang,Jianchao; Liu,Bing; Wang,Linhui

doi:10.3892/ol.2018.9412

Pyk2 promotes tumor progression in renal cell carcinoma

Authors:
- Tangliang Zhao
- Yi Bao
- Xin Lu
- Yi He
- Xinxin Gan
- Jianchao Wang
- Bing Liu
- Linhui Wang
View Affiliations

Affiliations: Department of Urology, Changzheng Hospital, The Second Military Medical University, Shanghai 200001, P.R. China, Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200003, P.R. China, Department of Urology, The First Hospital of Jiaxing, Jiaxing, Zhejiang 314000, P.R. China
Published online on: September 6, 2018 https://doi.org/10.3892/ol.2018.9412
Pages: 5953-5959
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Proline‑rich tyrosine kinase 2 (Pyk2), a member of the focal adhesion kinase family, has recently been associated with tumor development. However, the role of Pyk2 in renal cell carcinoma (RCC) remains unexplored. The present study investigated the expression pattern, clinical significance, and function of Pyk2 in RCC. By using a reverse transcription‑quantitative polymerase chain reaction, tissue microarray and immunohistochemistry, it was demonstrated that RCC tissues display a higher Pyk2 expression compared with paired adjacent nontumor tissues. Furthermore, it was revealed that Pyk2 upregulation was associated with poor clinical outcomes in patients with RCC. By using loss‑of‑function approaches, it was demonstrated that Pyk2 knockdown reduced cell viability, invasive ability and migratory ability, and increased apoptosis in RCC cell lines. In contrast, Pyk2 overexpression promoted tumor cell proliferation, invasion and migration and reduced apoptosis. Collectively, the results of the present study present the tumor‑promoting function of Pyk2 in RCC and thus provide molecular evidence for novel tyrosine kinase inhibitors as novel therapeutic options for RCC.

View Figures

View References

1	Busch J, Ralla B, Jung M, Wotschofsky Z, Trujillo-Arribas E, Schwabe P, Kilic E, Fendler A and Jung K: Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas. J Exp Clin Cancer Res. 34:612015. View Article : Google Scholar : PubMed/NCBI
2	Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
3	Ljungberga B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF and Sinescu IC: European Association of Urology Guideline Group: EAU guidelines on renal cell carcinoma: The 2010 update. Eur Urol. 58:398–406. 2010. View Article : Google Scholar : PubMed/NCBI
4	Sekar RR, De La Calle CM, Patil D, Holzman SA, Baum Y, Sheikh U, Huang JH, Osunkoya AO, Pollack BP, Kissick HT, et al: Major histocompatibility complex I upregulation in clear cell renal cell carcinoma is associated with increased survival. Asian J Urol. 3:75–81. 2016. View Article : Google Scholar : PubMed/NCBI
5	Gong J, Maia MC, Dizman N, Govindarajan A and Pal SK: Metastasis in renal cell carcinoma: Biology and implications for therapy. Asian J Urol. 3:286–292. 2016. View Article : Google Scholar : PubMed/NCBI
6	Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA and Belldegrun AS: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 20:4559–4566. 2002. View Article : Google Scholar : PubMed/NCBI
7	Zhang B, Yin C, Li H, Shi L, Liu N, Sun Y, Lu S, Liu Y, Sun L, Li X, et al: Nir1 promotes invasion of breast cancer cells by binding to chemokine (C-C motif) ligand 18 through the PI3K/Akt/GSK3β/Snail signalling pathway. Eur J Cancer. 49:3900–3913. 2013. View Article : Google Scholar : PubMed/NCBI
8	Wang Q, Tang Y, Yu H, Yin Q, Li M, Shi L, Zhang W, Li D and Li L: CCL18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog. 55:1688–1699. 2016. View Article : Google Scholar : PubMed/NCBI
9	Okigaki M, Davis C, Falasca M, Harroch S, Felsenfeld DP, Sheetz MP and Schlessinger J: Pyk2 regulates multiple signaling events crucial for macrophage morphology and migration. Proc Natl Acad Sci USA. 100:10740–10745. 2003. View Article : Google Scholar : PubMed/NCBI
10	Sun CK, Man K, Ng KT, Ho JW, Lim ZX, Cheng Q, Lo CM, Poon RT and Fan ST: Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation. Carcinogenesis. 29:2096–2105. 2008. View Article : Google Scholar : PubMed/NCBI
11	Zhang Y, Moschetta M, Huynh D, Tai YT, Zhang Y, Zhang W, Mishima Y, Ring JE, Tam WF, Xu Q, et al: Pyk2 promotes tumor progression in multiple myeloma. Blood. 124:2675–2686. 2014. View Article : Google Scholar : PubMed/NCBI
12	Lev S, Hernandez J, Martinez R, Chen A, Plowman G and Schlessinger J: Identification of a novel family of targets of PYK2 related to Drosophila retinal degeneration B (rdgB) protein. Mol Cell Biol. 19:2278–2288. 1999. View Article : Google Scholar : PubMed/NCBI
13	Sun CK, Ng KT, Lim ZX, Cheng Q, Lo CM, Poon RT, Man K, Wong N and Fan ST: Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition. PLoS One. 6:e188782011. View Article : Google Scholar : PubMed/NCBI
14	Naylor TL, Greshock J, Wang Y, Colligon T, Yu QC, Clemmer V, Zaks TZ and Weber BL: High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res. 7:R1186–R1198. 2005. View Article : Google Scholar : PubMed/NCBI
15	Wendt MK, Schiemann BJ, Parvani JG, Lee YH, Kang Y and Schiemann WP: TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer. Oncogene. 32:2005–2015. 2013. View Article : Google Scholar : PubMed/NCBI
16	Selitrennik M and Lev S: PYK2 integrates growth factor and cytokine receptors signaling and potentiates breast cancer invasion via a positive feedback loop. Oncotarget. 6:22214–22226. 2015. View Article : Google Scholar : PubMed/NCBI
17	Kuang BH, Zhang MQ, Xu LH, Hu LJ, Wang HB, Zhao WF, Du Y and Zhang X: Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small-cell lung cancer progression and patients' overall survival. Br J Cancer. 109:1252–1263. 2013. View Article : Google Scholar : PubMed/NCBI
18	Li Z, Yuan X, Wu Z, Guo Z, Jiang P and Wen Z: Expressions of FAK and Pyk2 in human astrocytic tumors and their relationship with angiogenesis. Chin-Ger J Clin Oncol. 7:658–660. 2008. View Article : Google Scholar
19	Yue Y, Li ZN, Fang QG, Zhang X, Yang LL, Sun CF and Liu FY: The role of Pyk2 in the CCR7-mediated regulation of metastasis and viability in squamous cell carcinoma of the head and neck cells in vivo and in vitro. Oncol Rep. 34:3280–3287. 2015. View Article : Google Scholar : PubMed/NCBI
20	Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, et al: Guideline for management of the clinical T1 renal mass. J Urol. 182:1271–1279. 2009. View Article : Google Scholar : PubMed/NCBI
21	Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
22	Taneja SS: Re: Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: Are further improvements needed? J Urol. 185:12232011. View Article : Google Scholar : PubMed/NCBI
23	Gupta K, Miller JD, Li JZ, Russell MW and Charbonneau C: Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev. 34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
24	Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S and Mazumdar M: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 22:454–463. 2004. View Article : Google Scholar : PubMed/NCBI
25	Weinstock M and McDermott D: Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol. 7:365–377. 2015. View Article : Google Scholar : PubMed/NCBI